Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CCND1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CCND1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CCND1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CCND1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/CCND1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CCND1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CCND1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CCND1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CCND1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CCND1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CCND1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003110011 | Liver | Cirrhotic | animal organ regeneration | 35/4634 | 76/18723 | 4.26e-05 | 5.03e-04 | 35 |
GO:00459313 | Liver | Cirrhotic | positive regulation of mitotic cell cycle | 49/4634 | 121/18723 | 9.47e-05 | 1.01e-03 | 49 |
GO:00447721 | Liver | Cirrhotic | mitotic cell cycle phase transition | 139/4634 | 424/18723 | 1.02e-04 | 1.06e-03 | 139 |
GO:003109911 | Liver | Cirrhotic | regeneration | 71/4634 | 198/18723 | 3.02e-04 | 2.65e-03 | 71 |
GO:1901990 | Liver | Cirrhotic | regulation of mitotic cell cycle phase transition | 100/4634 | 299/18723 | 4.13e-04 | 3.41e-03 | 100 |
GO:009742111 | Liver | Cirrhotic | liver regeneration | 18/4634 | 35/18723 | 6.04e-04 | 4.67e-03 | 18 |
GO:00323551 | Liver | Cirrhotic | response to estradiol | 51/4634 | 141/18723 | 1.60e-03 | 1.04e-02 | 51 |
GO:001021211 | Liver | Cirrhotic | response to ionizing radiation | 53/4634 | 148/18723 | 1.70e-03 | 1.08e-02 | 53 |
GO:2000045 | Liver | Cirrhotic | regulation of G1/S transition of mitotic cell cycle | 51/4634 | 142/18723 | 1.91e-03 | 1.20e-02 | 51 |
GO:00000821 | Liver | Cirrhotic | G1/S transition of mitotic cell cycle | 72/4634 | 214/18723 | 2.07e-03 | 1.28e-02 | 72 |
GO:00614585 | Liver | Cirrhotic | reproductive system development | 132/4634 | 427/18723 | 2.07e-03 | 1.28e-02 | 132 |
GO:00486085 | Liver | Cirrhotic | reproductive structure development | 131/4634 | 424/18723 | 2.19e-03 | 1.34e-02 | 131 |
GO:00315712 | Liver | Cirrhotic | mitotic G1 DNA damage checkpoint | 15/4634 | 30/18723 | 2.45e-03 | 1.47e-02 | 15 |
GO:0043627 | Liver | Cirrhotic | response to estrogen | 30/4634 | 75/18723 | 2.52e-03 | 1.51e-02 | 30 |
GO:005087812 | Liver | Cirrhotic | regulation of body fluid levels | 118/4634 | 379/18723 | 2.65e-03 | 1.55e-02 | 118 |
GO:00448192 | Liver | Cirrhotic | mitotic G1/S transition checkpoint | 15/4634 | 31/18723 | 3.68e-03 | 2.02e-02 | 15 |
GO:00454711 | Liver | Cirrhotic | response to ethanol | 48/4634 | 137/18723 | 4.45e-03 | 2.35e-02 | 48 |
GO:00427701 | Liver | Cirrhotic | signal transduction in response to DNA damage | 58/4634 | 172/18723 | 5.00e-03 | 2.59e-02 | 58 |
GO:007190011 | Liver | Cirrhotic | regulation of protein serine/threonine kinase activity | 110/4634 | 359/18723 | 6.19e-03 | 3.08e-02 | 110 |
GO:00448431 | Liver | Cirrhotic | cell cycle G1/S phase transition | 77/4634 | 241/18723 | 6.68e-03 | 3.30e-02 | 77 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCND1 | SNV | Missense_Mutation | rs755986542 | c.778N>T | p.Arg260Cys | p.R260C | P24385 | protein_coding | deleterious(0.03) | benign(0.218) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCND1 | SNV | Missense_Mutation | | c.859N>A | p.Pro287Thr | p.P287T | P24385 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-JW-A5VH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
CCND1 | SNV | Missense_Mutation | | c.859N>A | p.Pro287Thr | p.P287T | P24385 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
CCND1 | SNV | Missense_Mutation | novel | c.701C>T | p.Ser234Phe | p.S234F | P24385 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3692-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | PD |
CCND1 | SNV | Missense_Mutation | | c.859C>A | p.Pro287Thr | p.P287T | P24385 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCND1 | SNV | Missense_Mutation | | c.405G>T | p.Glu135Asp | p.E135D | P24385 | protein_coding | tolerated(0.69) | benign(0) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CCND1 | SNV | Missense_Mutation | | c.860N>A | p.Pro287His | p.P287H | P24385 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCND1 | SNV | Missense_Mutation | | c.694N>C | p.Phe232Leu | p.F232L | P24385 | protein_coding | tolerated(1) | benign(0) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
CCND1 | SNV | Missense_Mutation | | c.718G>A | p.Asp240Asn | p.D240N | P24385 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCND1 | SNV | Missense_Mutation | | c.512C>T | p.Ala171Val | p.A171V | P24385 | protein_coding | tolerated(0.16) | benign(0.001) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | NIFEDIPINE | NIFEDIPINE | 10051745 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | fluorouracil | FLUOROURACIL | 23567490 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | methotrexate | METHOTREXATE | 12972956,16870553 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | lapatinib | LAPATINIB | |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | ACETAMINOPHEN | ACETAMINOPHEN | 11896290 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | ABT-263 | NAVITOCLAX | |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | PALBOCICLIB | PALBOCICLIB | 24417566 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | TROGLITAZONE | TROGLITAZONE | 14764597 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | MTX | METHOTREXATE | 12972956 |
595 | CCND1 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, KINASE, DRUG RESISTANCE | | MPA | PROGESTERONE | 16123159 |